Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

MICHAEL MCCOY The Swiss drug firm Novartis has agreed to acquire a company it cofounded. Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...